Bright Minds Biosciences Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Bright Minds Biosciences hat ein Gesamteigenkapital von CA$5.7M und eine Gesamtverschuldung von CA$0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CA$6.5M bzw. CA$845.8K.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

CA$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CA$5.93m
Eigenkapital	CA$5.69m
Gesamtverbindlichkeiten	CA$845.79k
Gesamtvermögen	CA$6.53m

Jüngste Berichte zur Finanzlage

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04

Recent updates

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Aug 19

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Mar 07

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Nov 04

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: DRUGDie kurzfristigen Aktiva des Unternehmens (CA$6.5M) übersteigen seine kurzfristigen Passiva (CA$845.8K).

Langfristige Verbindlichkeiten: DRUG hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: DRUG ist schuldenfrei.

Schulden abbauen: DRUG hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: DRUG auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: DRUG hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 24.6% pro Jahr abnimmt

Bright Minds Biosciences Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Bright Minds Goes for 5:1 Shares Consolidation, Hopes to Regain Nasdaq Compliance

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

Recent updates

New major risk - Financial position

High number of new and inexperienced directors

Bright Minds Biosciences Inc., Annual General Meeting, Mar 22, 2024

Less than half of directors are independent

Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding

New major risk - Market cap size

Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101

Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101

Less than half of directors are independent

Bright Minds Goes for 5:1 Shares Consolidation, Hopes to Regain Nasdaq Compliance

Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Inc. Announces Resignation of Williamson from Board of Directors and Audit Committee

Bright Minds Biosciences Inc., Annual General Meeting, Mar 24, 2023

Bright Minds Biosciences Inc. Announces the Resignation of Doug Williamson from Board of Directors

Bright Minds Biosciences Inc. announced that it expects to receive CAD 2.05 million in funding

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer, Effective December 1, 2022

High number of new and inexperienced directors

Bright Minds Biosciences Announces Executive Changes

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 4.0012 million.

Here's Why Bright Minds Biosciences (CSE:DRUG) Must Use Its Cash Wisely

Bright Minds Biosciences Announces Changes to Its Executive Leadership Team

High number of new and inexperienced directors

We Think Bright Minds Biosciences (CSE:DRUG) Needs To Drive Business Growth Carefully

Bright Minds Biosciences Provides Scientific Update on Its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

We're Hopeful That Bright Minds Biosciences (CSE:DRUG) Will Use Its Cash Wisely

High number of new and inexperienced directors

Bright Minds Biosciences Inc. Provides Scientific Update

CEO & Director recently bought CA$116k worth of stock

Bright Minds Biosciences Inc., Annual General Meeting, May 18, 2021

Bright Minds Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 25.00371 million.

Bright Minds Biosciences Inc. Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

Bright Minds Biosciences Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating

Bright Minds Biosciences Announces Scientific Advisory Team Appointment

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen